AVENUE THERAPEUTICS, INC. (ATXI) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US05360L3042

Price
0.28 USD
Market cap
922,590.76 USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

AVENUE THERAPEUTICS, INC. financials

Fiscal year2025
Revenue1.40 m USD
Operating income-3.08 m USD
EBIT-3.07 m USD
Net income-2.91 m USD

Full history since 2015, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About AVENUE THERAPEUTICS, INC.

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include ATX-04, a small molecule therapy for the treatment of Pompe disease; and intravenous tramadol, a schedule IV opioid to treat post-operative acute pain. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.